MYCRONIC

Q4

Year-end Report January-December 2025

Fourth quarter

- Order intake amounted to SEK 1,939 (2,381) million, a decline of 19 percent
- Net sales declined 2 percent to SEK 2,021 (2,059) million. Based on constant exchange rates, net sales increased 10 percent
- EBIT amounted to SEK 342 (527) million and the EBIT margin was 17 (26) percent
- Earnings per share were SEK 1.42 (2.36) before dilution and SEK 1.42 (2.35) after dilution

January-December

- Order intake amounted to SEK 7,757 (7,611) million, an increase of 2 percent
- Net sales increased 12 percent to SEK 7,938 (7,057) million. Based on constant exchange rates, net sales increased 20 percent
- EBIT amounted to SEK 1,940 (2,021) million and the EBIT margin was 24 (29) percent
- Earnings per share were SEK 7.99 (8.62) before and after dilution
- The Board of Directors proposes a dividend of SEK 3.25 (2.75) per share to the 2026 Annual General Meeting. No extra dividend (SEK 1.00) is proposed

"Order intake in the fourth quarter amounted to SEK 1,939 million, which constituted a 19 percent decline compared with the stellar fourth quarter last year. Net sales reached SEK 2,021 million, where declines in Pattern Generators, PCB Assembly Solutions and High Volume were almost fully compensated for by a strong development in Global Technologies. EBIT for the quarter declined to SEK 342 million, corresponding to an EBIT margin of 17 percent. 2025 was a record year in terms of both order intake and net sales. We also signed agreements to acquire four new exciting companies. Furthermore, the successful relocation during the year of PCB Assembly Solutions to Kista, Stockholm, has laid the foundation for future growth for both PCB Assembly Solutions and Pattern Generators, with both divisions now having improved their production possibilities", says Anders Lindqvist, President and CEO.

Outlook 2026

It is the Board of Directors' opinion that net sales for 2026 will be at a level of SEK 8.25 billion.

	Q4		Jan-Dec	
Group summary	**2025**	**2024**	**2025**	**2024**
Order intake, SEK million	1,939	2,381	7,757	7,611
Net Sales, SEK million	2,021	2,059	7,938	7,057
Book-to-bill	1.0	1.2	1.0	1.1
Order backlog, SEK million	4,681	4,702	4,681	4,702
Gross margin, %	46.8%	48.8%	52.4%	52.7%
EBIT, SEK million	342	527	1,940	2,021
EBIT margin, %	16.9%	25.6%	24.4%	28.6%
Earnings per share before dilution, SEK*	1.42	2.36	7.99	8.62
Earnings per share after dilution, SEK*	1.42	2.35	7.99	8.62
Cash Flow, SEK million	309	443	-585	822
Changes in Net Sales				
Total growth, %	-2%	5%	12%	24%
Organic growth, %	3%	2%	15%	25%
Growth from acquisitions/divestments, %	7%	2%	4%	1%
Currency effects, %	-11%	0%	-7%	-2%

*Recalculated to reflect the share split executed on June 3, 2025, whereby one existing share was split into two shares.

MYCRONIC

CEO comments

Order intake in the fourth quarter amounted to SEK 1,939 million, which constituted a 19 percent decline compared with the stellar fourth quarter last year. Net sales reached SEK 2,021 million, where declines in Pattern Generators, PCB Assembly Solutions and High Volume were almost fully compensated for by a strong development in Global Technologies. EBIT for the quarter declined to SEK 342 million, corresponding to an EBIT margin of 17 percent.

In Pattern Generators, the semiconductor photomask market showed positive development, mainly driven by AI applications, which are predominantly produced on leading-edge nodes. Despite this, a significant share of photomasks are written using laser-based mask writers, including writing a second-layer on the most advanced photomasks. Hence, the AI trend is also positive for the demand of laser-based mask writers. The display photomask market remained stable. Pattern Generators continued increasing its investments in new core technologies, aimed at broadening the offering to the existing customer base through the development of a new semiconductor photomask inspection product, thereby supporting continued organic growth. The division received orders for one Prexision 8 Evo, one FPS 6100 Evo and three SLXs.

For PCB Assembly Solutions, the European market continued to be weak, the US market was stable, and Asia showed positive development. In November, the division participated at the biennial Productronica trade show, in Munich. Despite the sluggish European market, the mood at Productronica was upbeat. PCB Assembly Solutions' launch of GenI received strong interest, a solution designed to liberate electronics manufacturers from the complexities of traditional Automated Optical Inspection (AOI) programming.

High Volume also participated at Productronica, generating a substantial amount of leads for the European market. A new production facility in Thailand was inaugurated during the quarter, with many customers present. The plans to partially list Axxon on a stock exchange in China have been put on hold. A broad Employee Stock Option Program (ESOP) has been launched for the division, in order to attract and retain top talent.

For Global Technologies, the market for the PCB Test business line remained strong. Solid demand from the AI segment transformed into high investments from PCB manufacturers. Investments in Southeast Asia also continued. The Die Bonding business line experienced good demand from the AI data center segment. The business line Applied Plasma also noted a good development in the quarter.

After the end of the period, Global Technologies acquired ETZ, a company based in Germany, which manufactures test probes. ETZ's net sales in 2025 amounted to almost EUR 4 million, of which sales to Mycronic made up around 85 percent. The company will become part of the PCB Test business line.

2025 was a record year in terms of both order intake and net sales. The gross margin was stable and we increased our investments in expanding the organization, in particular R&D, which impacted EBIT. We also signed agreements to acquire four new exciting companies. Furthermore, the successful relocation during the year of PCB Assembly Solutions to Kista, Stockholm, has laid the foundation for future growth for both PCB Assembly Solutions and Pattern Generators, with both divisions now having improved their production possibilities.

Anders Lindqvist, President and CEO

Order intake and net sales, rolling 12 months



Gross and EBIT margin, rolling 12 months



MYCRONIC

Financial performance

GROUP

	Q4		Jan-Dec	
	2025	2024	2025	2024
Order intake, SEK million	1,939	2,381	7,757	7,611
Order backlog, SEK million	4,681	4,702	4,681	4,702
Net Sales, SEK million	2,021	2,059	7,938	7,057
Gross profit, SEK million	945	1,004	4,163	3,719
Gross margin, %	46.8%	48.8%	52.4%	52.7%
EBIT, SEK million	342	527	1,940	2,021
EBIT margin, %	16.9%	25.6%	24.4%	28.6%
EBITDA, SEK million	433	599	2,270	2,287

Order intake in the fourth quarter declined 19 percent to SEK 1,939 (2,381) million, explained mainly by Pattern Generators and despite Global Technologies showing a very strong development. For the full year, order intake increased 2 percent to SEK 7,757 (7,611) million. The Group's order backlog at the end of the year was SEK 4,681 (4,702) million.

Net sales in the quarter decreased 2 percent to SEK 2,021 (2,059) million, where declines in Pattern Generators, PCB Assembly Solutions and High Volume were almost fully compensated for by a healthy development in Global Technologies. For the full year, net sales increased 12 percent to SEK 7,938 (7,057) million. Net sales for the quarter were impacted by currency effects of SEK -239 million and for full year by SEK -514 million.

The gross margin was 47 (49) percent, with declines in Pattern Generators and PCB Assembly Solutions and an increase in High Volume. For the full year, the gross margin was 52 (53) percent.

EBIT for the quarter declined to SEK 342 (527) million, corresponding to an EBIT margin of 17 (26) percent. For the full year, EBIT amounted to SEK 1,940 (2,021) million, representing an EBIT margin of 24 (29) percent. Acquisition-related costs amounted to SEK 51 (21) million for the quarter and SEK 196 (74) million for the full year.

Cash flow and financial position

Consolidated cash and cash equivalents at the end of the year amounted to SEK 2,323 (3,014) million. Cash flow for the year amounted to SEK -585 (822) million. Cash flow from operating activities amounted to SEK 1,407 (1,874) million. Working capital increased during the year, with a cash flow impact of SEK -549 (-324) million, driven primarily by higher inventory and lower advance payments from customers.

Investing activities generated a cash flow of SEK -1,129 (-500) million during the year, with the acquisitions of Hprobe, RoBAT and Surfx accounting for SEK -920 million, capitalization of product development for SEK -64 (-84) million and investments in property, plant and equipment for SEK -91 (-126) million. Financing activities generated a cash flow of SEK -862 (-552) million, of which SEK -734 (-441) million related to dividends to shareholders. At the end of the year, Mycronic had a net cash position of SEK 1,974 (2,795) million.

Sustainability

Data as per December 31 shows progress on diversity. The share of women in the workforce, as well as in managerial roles, increased in 2025. Notably, the Pattern Generators division reported a rise in female representation in its workforce, from 19 to 22 percent. The "Diversity and inclusion" category also improved in the annual employee engagement survey and is now its highest-rated topic. During the quarter, initiatives were implemented aimed at enhancing sustainability expertise within the Group. Sales representatives received training, and purchasing managers participated in seminars focused on strengthening supply chain due diligence.

MYCRONIC

PATTERN GENERATORS

	Q4		Jan-Dec	
	2025	2024	2025	2024
Order intake, SEK million	545	1,144	2,481	3,262
Order backlog, SEK million	2,582	3,334	2,582	3,334
Net Sales, SEK million	577	702	3,232	2,997
Gross profit, SEK million	335	444	2,209	2,105
Gross margin, %	58.2%	63.3%	68.3%	70.2%
EBIT, SEK million	173	311	1,623	1,694
EBIT margin, %	30.1%	44.3%	50.2%	56.5%
EBITDA	192	329	1,699	1,756
R&D expenditures, SEK million	-124	-106	-445	-332
R&D costs, SEK million	-117	-91	-420	-287

The semiconductor photomask market showed positive development, mainly driven by AI applications, which are predominantly produced on leading-edge nodes. Despite this, a significant share of photomasks are written using laser-based mask writers, including writing a second-layer on the most advanced photomasks. Hence, the AI trend is also positive for the demand of laser-based mask writers. The display photomask market remained stable. Pattern Generators continued increasing its investments in new core technologies, aimed at broadening the offering to the existing customer base through the development of a new semiconductor photomask inspection product, thereby supporting continued organic growth. The acquisition of Cowin DST remains pending regulatory approval in South Korea.

The division received orders for one Prexision 8 Evo, one FPS 6100 Evo and three SLXs during the quarter. Order intake decreased 52 percent compared with the stellar fourth quarter last year, to SEK 545 (1,144) million. For the full year, order intake decreased 24 percent to SEK 2,481 (3,262) million. The business is characterized by fluctuations over time and performance should be viewed from a long-term perspective.

The order backlog at the end of the year was SEK 2,582 (3,334) million and contained 18 systems, with planned deliveries as follows:

2026 Q1: 1 Prexision 8000 Evo, 1 Prexision 8 Evo, 1 FPS Evo, 4 SLXs
2026 Q2: 1 Prexision 8 Evo, 1 Prexision 8 Entry Evo, 2 Prexision Lite 8 Evo
2026 Q3: 1 Prexision Lite 8 Evo, 1 FPS 6100 Evo, 1 Prexision MMS
2026 Q4: 1 SLX
2027 Q1: 2 Prexision 8 Evo
2027 Q4: 1 SLX

Compared to the delivery timetable presented in the most recent interim report, delivery of a Prexision 8 Entry Evo has been moved from the first to the second quarter of 2026 and delivery of an SLX has been moved from the second to the fourth quarter of 2026.

During the quarter, Pattern Generators delivered one Prexision Lite 8 Evo, one FPS 6100 Evo and three SLXs. In addition, revenue for an SLX installed for a qualification project, was recognized in the fourth quarter. This is to be compared with deliveries of one Prexision 8 Entry Evo, five SLXs and one MMX in the corresponding period of the preceding year. Net sales declined 18 percent to SEK 577 (702) million. For the full year, net sales increased 8 percent to SEK 3,232 (2,997) million. Net sales for the quarter were impacted by currency effects of SEK -80 million and for the full year by SEK -197 million.

The gross margin for the final quarter of the year amounted to 58 (63) percent, the reduction reflecting a less favorable product mix. For the full year, the gross margin amounted to 68 (70) percent.

EBIT decreased to SEK 173 (311) million, corresponding to an EBIT margin of 30 (44) percent. For the full year, EBIT was SEK 1,623 (1,694) million, equalling an EBIT margin of 50 (57) percent. Pattern Generators was not charged with acquisition-related costs.

R&D costs for the quarter amounted to SEK 117 (91) million and SEK 420 (287) million for the full year. The capitalization of development costs amounted to SEK 7 (16) million for the quarter and SEK 25 (45) million for the full year.

PCB ASSEMBLY SOLUTIONS

	Q4		Jan-Dec	
	2025	2024	2025	2024
Order intake, SEK million	362	389	1,417	1,471
Order backlog, SEK million	147	102	147	102
Net Sales, SEK million	438	486	1,372	1,489
Gross profit, SEK million	177	219	520	602
Gross margin, %	40.5%	45.0%	37.9%	40.5%
EBIT, SEK million	59	106	79	156
EBIT margin, %	13.4%	21.8%	5.8%	10.5%
EBITDA	71	118	125	202
R&D expenditures, SEK million	-50	-51	-197	-207
R&D costs, SEK million	-44	-43	-172	-176

The European market continued to be weak, the US market was stable, and Asia showed positive development. In November, the division participated at the biennial Productronica trade show, in Munich. Despite the sluggish European market, the mood at Productronica was upbeat. PCB Assembly Solutions' launch of GenI received strong interest, a solution designed to liberate electronics manufacturers from the complexities of traditional Automated Optical Inspection (AOI) programming. The division also introduced the MYPro A41, a pick-and-place machine for large PCBs.

Order intake decreased 7 percent during the quarter to SEK 362 (389) million. For the full year, order intake decreased 4 percent to SEK 1,417 (1,471) million. The order backlog at the end of the year amounted to SEK 147 (102) million.

Net sales declined 10 percent during the quarter to SEK 438 (486) million. For the full year, net sales decreased 8 percent to SEK 1,372 (1,489) million. Net sales for the quarter were impacted by currency effects of SEK -40 million and for the full year by SEK -78 million.

The gross margin for the quarter was 40 (45) percent and for the full year 38 (40) percent.

EBIT declined to SEK 59 (106) million, corresponding to an EBIT margin of 13 (22) percent. EBIT for the full year decreased to SEK 79 (156) million, corresponding to an EBIT margin of 6 (11) percent. Acquisition-related costs amounted to SEK 1 (1) million during the quarter and to SEK 2 (6) million for the full year.

R&D costs for the quarter amounted to SEK 44 (43) million and SEK 172 (176) million for the full year. The capitalization of development costs amounted to SEK 7 (8) million for the quarter and SEK 26 (36) million for the full year.

HIGH VOLUME

	Q4		Jan-Dec	
	2025	2024	2025	2024
Order intake, SEK million	271	387	1,651	1,523
Order backlog, SEK million	683	752	683	752
Net Sales, SEK million	448	467	1,720	1,434
Gross profit, SEK million	184	163	690	555
Gross margin, %	41.1%	34.8%	40.1%	38.7%
EBIT, SEK million	55	76	267	223
EBIT margin, %	12.3%	16.3%	15.5%	15.6%
EBITDA	59	80	281	234
R&D expenditures, SEK million	-54	-43	-183	-154
R&D costs, SEK million	-54	-44	-183	-151

High Volume participated at the Productronica trade show in Munich, generating a substantial amount of leads for the European market. A new production facility in Thailand was inaugurated during the quarter, with many customers present.

The plans to partially list Axxon on a stock exchange in China have been put on hold. A broad Employee Stock Option Program (ESOP) has been launched for the division, with 120 participants, where employees are entitled to purchase shares in Axxon at a discount. The cost of the ESOP, consisting of both the discount and a potential increase in the value of the stock, will be incurred during the lock-in period 2025-2027. For 2026-2027, the discount cost is estimated at SEK 90 million per year. The discount will impact EBIT and any change in the value of the stock will be recorded in the income statement under financial income and expense.

Order intake decreased 30 percent during the quarter and amounted to SEK 271 (387) million. For the full year, order intake increased 8 percent to SEK 1,651 (1,523) million. The order backlog at the end of the year was SEK 683 (752) million.

Net sales amounted to a healthy SEK 448 (467) million, which still constituted a 4 percent decline. For the full year, net sales increased 20 percent to SEK 1,720 (1,434) million. Net sales for the quarter were impacted by currency effects of SEK -66 million and for the full year by SEK -144 million.

The gross margin for the quarter was 41 (35) percent and for the full year 40 (39) percent.

EBIT was SEK 55 (76) million, corresponding to an EBIT margin of 12 (16) percent. ESOP had an EBIT impact of -23 MSEK. There was also a one-off reversal of a personnel related provision, which had a positive EBIT impact of 13 MSEK. For the full year, EBIT amounted to SEK 267 (223) million, equalling an EBIT margin of 16 (16) percent. Acquisition-related costs amounted to SEK 1 (3) million for the quarter and SEK 7 (3) million for the full year.

R&D costs for the quarter amounted to SEK 54 (44) million and SEK 183 (151) million for the full year. The capitalization of development costs amounted to SEK 0 (0) million for the quarter and SEK 2 (4) million for the full year.

MYCRONIC

GLOBAL TECHNOLOGIES

	Q4		Jan-Dec	
	2025	2024	2025	2024
Order intake, SEK million	773	461	2,227	1,355
Order backlog, SEK million	1,269	514	1,269	514
Net Sales, SEK million	570	403	1,632	1,138
Gross profit, SEK million	256	179	756	455
Gross margin, %	44.9%	44.4%	46.3%	40.0%
EBIT, SEK million	118	86	225	113
EBIT margin, %	20.7%	21.3%	13.8%	10.0%
EBITDA	147	102	322	177
R&D expenditures, SEK million	-52	-31	-170	-101
R&D costs, SEK million	-63	-39	-204	-134

The market for the PCB Test business line remained strong. Solid demand from the AI segment transformed into high investments from PCB manufacturers, both those already present in the AI segment and those with ambitions to enter. Investments in Southeast Asia also continued. The Die Bonding business line experienced good demand from the AI data center segment. In addition, the aerospace & defense and medical segments showed healthy demand. The business line Applied Plasma also noted a good development in the quarter.

Order intake increased 68 percent during the quarter to SEK 773 (461) million. For the full year, order intake increased 64 percent to SEK 2,227 (1,355) million. Order intake excluding acquisitions increased 45 percent during the quarter and 41 percent for the full year. The order backlog at the end of the quarter amounted to SEK 1,269 (514) million.

Net sales increased 41 percent to SEK 570 (403) million, with acquired companies Hprobe, RoBAT and Surfx contributing SEK 131 million. For the full year, net sales increased 43 percent to SEK 1,632 (1,138) million. Net sales for the quarter were impacted by currency effects of SEK -53 million and for the full year by SEK -94 million. Organic net sales increased 19 percent during the quarter and 26 percent for the full year.

The gross margin for the quarter was 45 (44) percent and for the full year 46 (40) percent.

EBIT was SEK 118 (86) million, corresponding to an EBIT margin of 21 (21) percent. For the full year, EBIT amounted to SEK 225 (113) million, corresponding to an EBIT margin of 14 (10) percent. Hprobe, RoBAT and Surfx had an EBIT impact of SEK -6 million during the quarter and SEK -55 million for the full year. Acquisition-related costs amounted to SEK 50 (15) million during the quarter and to SEK 176 (54) million for the full year.

R&D costs for the quarter amounted to SEK 63 (39) million and SEK 204 (134) million for the full year. The capitalization of development costs amounted to SEK 2 (-) million for the quarter and SEK 11 (-) million for the full year.

After the end of the period, Global Technologies acquired ETZ, a company based in Germany, which manufactures test probes. ETZ's net sales in 2025 amounted to almost EUR 4 million, of which sales to Mycronic made up around 85 percent. The company will become part of the PCB Test business line.

MYCRONIC

Electronics industry

The global electronics industry is assessed to have grown 8.5 percent in 2025 to USD 2,770 billion[1]. For the full year 2025, the semiconductor market is forecast to have grown 20.4 percent to the equivalent of USD 756 billion[1].

OUTLOOK

Annual growth for the electronics industry is forecast at 5.9 percent for the period 2024-2029[1]. Segments with the strongest expected growth during this five-year period are electronics for data centers, aerospace & defense, industrial applications and communications. The electronics industry is forecast to grow 5.8 percent in 2026. Growth is expected to occur in all segments, except in the consumer segment for TVs. The semiconductor market is expected to grow 16.0 percent in 2026, driven by demand for AI chips for data centers and higher memory prices. Market growth is forecast to be positive during the 2024-2029 period as a whole, with annual growth of 10.1 percent[1]. The display market declined 1.8 percent in 2025 to USD 133 billion[2], mainly due to OLED display price pressure, after a year of very strong growth of 26.1 percent during 2024 for the OLED display market. For 2026, the display market is forecast to decline a further 1.5 percent due to continued price pressure in both LCD and OLED displays. During the 2025-2030 period, the display market is expected to demonstrate annual growth of 1.6 percent[2]. The long-term trend toward a larger share of advanced OLED displays is forecast to continue.

Size/growth	2026F	2025	2024
Electronics industry, percentual change[1]	+5.8%	+8.5%	+5.0%
Semiconductor industry, percentual change[1]	+16.0%	+20.4%	+19.2%
SMT component mounting, percentual change[3]	NA	+25.2%	-7.7%
Dispensing, USD million[4]	NA	NA	750
Displays, USD, billion[2]	131	133	135
Photomasks for displays, percentual change in value[5]	-0.4%	+4.9%	+1.4%
Photomasks for semiconductors, percentual change in value[6]	+15.0%	+17.9%	+15.5%
Display photomask area, thousand sq. meters[5]	23.0	22.8	22.0

SMT AND DISPENSING MARKET AREA

The global market for SMT equipment has annual sales of approximately USD 3,900 million[7]. The segment SMT robots for component mounting grew 25.2 percent in 2025, to USD 2,600 million. Markets in Southeast Asia and China showed growth while North and South America were unchanged and Japan and Europe had a negative trend[3]. The dispensing equipment market increased 2.7 percent and had sales of USD 750 million[4] in 2024 - figures for 2025 are not yet available.

ASSEMBLY AUTOMATION AND TEST MARKET AREA

In die bonding, the market for optical components in data/telecommunications was USD 16.6 billion[8] in 2024. The market is expected to have grown 20.8 percent in 2025 and post annual growth of 16.9 percent during the 2025-2030 period, to USD 43.9 billion[8]. In electrical testing, the market for PCBs is assessed to have increased 15.4 percent in 2025, to USD 84.9 billion[9], and is expected to post annual growth of 8.2 percent during the 2024-2029 period, to USD 109.3 billion[9].

PATTERN GENERATORS MARKET AREA

PHOTOMASKS FOR DISPLAYS

The market is expected to have grown 4.9 percent in 2025, to USD 966 million[5,10]. This growth followed a positive development also in 2024 and display manufacturers continued to develop new LCD and OLED displays at a good pace. The market continues to be driven by an ongoing shift toward a higher proportion of advanced displays that require more, and more advanced, photomasks. The expectation for 2026 is that the photomask market will stabilize at the current level, showing a slight decline of 0.4 percent to USD 962 million[5,10]. The forecast for total area growth amounts to an average of 1.8 percent per year for 2025-2029[5]. Stronger growth for OLED photomasks is expected, with an annual average area growth of 5.1 percent for 2025-2029[5], which drives the need for photomasks produced by more advanced mask writers.

PHOTOMASKS FOR SEMICONDUCTORS

For 2025, the market is expected to have shown strong growth of 17.9 percent to USD 10.6 billion[6]. The market trend was mixed, with some segments and regions continuing to perform strongly, such as AI and advanced memory chips, although there were also weaker segments, such as semiconductors for the automotive industry. The expectation for 2026 is that the market will continue to perform positively, with growth of 15.0 percent to USD 12.2 billion[6]. The market value will continue to be primarily driven by the volume trend for the most advanced photomasks, which are mainly produced by E-beam mask writers. The market for laser-based mask writers is also expected to develop positively.

1) Prismark, latest forecast December 2025
2) Omdia, latest forecast January 2026
3) Protec MDC, January 2026
4) Prismark, April 2025 (annual update)
5) Omdia, July 2025 (annual update)
6) TechInsights, January 2026
7) Protec MDC, January 2025, Mycronic analysis, April 2025
8) Lightcounting, April 2025
9) Prismark, December 2025
10) 150 YEN/USD used by Mycronic for conversion

Other

PARENT COMPANY

Mycronic AB is the Group's Parent Company.

The Parent Company's net sales amounted to SEK 4,218 (4,062) million for the full year. EBIT amounted to SEK 1,117 (1,600) million.

Cash and cash equivalents at the end of the year amounted to SEK 1,378 million, compared with SEK 2,084 million at the end of 2024.

NOMINATION COMMITTEE

The Nomination Committee for Mycronic's 2026 Annual General Meeting has been appointed in accordance with the instructions for the Nomination Committee as decided by the 2025 Annual General Meeting. The Nomination Committee comprises: Henrik Blomquist (Bure Equity), Patrik Jönsson (SEB Funds), Celia Grip (Swedbank Robur), and Patrik Tigerschiöld (Chairman of Mycronic). The Nomination Committee represented 39.0 percent of votes and shares as of August 31, 2025.

ANNUAL GENERAL MEETING 2026

The Annual General Meeting will be held on May 6, 2026. The notification will be sent out in due course.

In line with the dividend policy, the Board of Directors proposes to the Annual General Meeting a dividend of SEK 3.25 (2.75) per share, totaling SEK 636.5 (538.5) million. No extra dividend (SEK 1.00) is proposed.

The record date for entitlement to the dividend is proposed as May 8, 2026. Provided the Meeting resolves in favor of the dividend proposal, the dividend will be paid on May 13, 2026.

FINANCIAL INFORMATION

Mycronic AB (publ) is listed on Nasdaq Stockholm, Large Cap. The information in this report is published in accordance with the EU Market Abuse Regulation and the Swedish Securities Act. The information was submitted for publication, through the contact persons stated below, at 8:00 a.m. CET on February 5, 2026.

Financial reports and press releases are published in Swedish and English and are available at mycronic.com.

This report was not reviewed by the company's auditor.

PRESENTATION

Mycronic will hold a presentation at 10:00 a.m. CET on February 5, 2026, with President and CEO Anders Lindqvist and CFO and Sr VP Corporate Development Pierre Brorsson. The presentation will be webcast.

FINANCIAL CALENDAR

Annual Report 2025	April 1, 2026
Interim Report January-March 2026	April 24, 2026
Annual General Meeting 2026	May 6, 2026
Interim Report January-June 2026	July 14, 2026
Capital Markets Day	August 31, 2026
Interim Report January-September 2026	October 22, 2026
Year-end report 2026	February 4, 2027

FOR ADDITIONAL INFORMATION, PLEASE CONTACT

Anders Lindqvist
President and CEO
Tel: +46 8 638 52 00
E-mail: anders.lindqvist@mycronic.com

Pierre Brorsson
CFO and Sr VP Corporate Development
Tel: +46 8 638 52 00
E-mail: pierre.brorsson@mycronic.com

Sven Chetkovich
Director Investor Relations
Tel: +46 70 558 39 19
E-mail: sven.chetkovich@mycronic.com

The Board of Directors and CEO certify that this year-end report provides a true and fair picture of the business activities, financial position and results of operations of the Parent Company and the Group and describes the significant risks and uncertainties to which the Parent Company and the Group are exposed.

Täby, February 5, 2026
Mycronic AB (publ)

Anders Lindqvist
President and CEO

Patrik Tigerschiöld Chairman	Arun Bansal Board member	Anna Belfrage Board member
Katarina Bonde Board member	Staffan Dahlström Board member	Jens Hinrichsen Board member
Bo Risberg Board member	Jörgen Lundberg Employee representative	Sahar Raouf Employee representative

Mycronic AB (publ)
Box 3141
SE-183 03 Täby, Sweden
Tel: +46 8 638 52 00

www.mycronic.com
Reg office: Stockholm
Reg no: 556351-2374

MYCRONIC

Group

Consolidated profit and loss accounts in summary, SEK million	Note	Q4 2025	Q4 2024	Jan-Dec 2025	Jan-Dec 2024
Net sales	5, 6	2,021	2,059	7,938	7,057
Cost of goods sold		-1,075	-1,055	-3,775	-3,338
Gross profit		**945**	**1,004**	**4,163**	**3,719**
Research and development	7	-277	-216	-978	-747
Selling expenses		-210	-172	-749	-628
Administrative expenses		-121	-102	-456	-361
Other income and expenses		5	12	-39	38
EBIT		**342**	**527**	**1,940**	**2,021**
Financial income and expenses		9	16	30	63
Profit/loss before tax		**351**	**543**	**1,970**	**2,084**
Tax		-76	-78	-410	-396
Net Profit/loss		**275**	**464**	**1,560**	**1,688**
Earnings per share before dilution, SEK		1.42	2.36	7.99	8.62
Earnings per share after dilution, SEK		1.42	2.35	7.99	8.62
Results attributable to owners of the Parent Company		277	460	1,560	1,683
Results attributable to non-controlling interests		-2	5	0	5
		275	**464**	**1,560**	**1,688**

Consolidated statement of comprehensive income in summary, SEK million	Q4 2025	Q4 2024	Jan-Dec 2025	Jan-Dec 2024
Net Profit/loss	**275**	**464**	**1 560**	**1 688**
Other comprehensive income				
Items not to be reclassified to profit/loss, after tax				
Actuarial profit/loss from defined benefits to employees	0	-2	0	-2
Net gain/loss on equity instruments designated at fair value through other comprehensive income	-	-	49	-
Items to be reclassified to profit/loss, after tax				
Translation differences at translating foreign entities	-88	155	-496	190
Changes in cash flow hedges	8	-119	188	-144
Total comprehensive income	**194**	**499**	**1 300**	**1 731**
Total comprehensive income attributable to owners of the Parent Company	192	492	1 301	1 724
Total comprehensive income attributable to non-controlling interests	2	7	-1	7
	194	**499**	**1 300**	**1 731**

Consolidated statements of financial position in summary, SEK million	Note	31 Dec 25	31 Dec 24
ASSETS			
Non-current assets			
Intangible assets	6, 8	3,524	2,686
Property, plant and equipment		699	574
Non-current receivables		59	59
Deferred tax assets		193	214
Total non-current assets		**4,474**	**3,533**
Current assets			
Inventories	6	2,150	2,056
Trade receivables	6	1,336	1,507
Other current receivables		640	301
Cash and cash equivalents		2,323	3,014
Total current assets		**6,449**	**6,879**
Total assets		**10,922**	**10,412**
EQUITY AND LIABILITIES			
Equity		**7,109**	**6,575**
Non-current liabilities			
Non-current interest-bearing liabilities		252	133
Deferred tax liabilities		526	405
Other non-current liabilities		237	94
Total non-current liabilities		**1,015**	**632**
Current liabilities			
Current interest-bearing liabilities		96	87
Trade payables		465	557
Other current liabilities		2,237	2,562
Total current liabilities		**2,798**	**3,205**
Total liabilities		**3,813**	**3,837**
Total equity and liabilities		**10,922**	**10,412**

MYCRONIC

Consolidated cash flow statements in summary, SEK million	Q4 2025	Q4 2024	Jan-Dec 2025	Jan-Dec 2024
Profit/loss before tax	351	543	1,970	2,084
Adjustments for non-cash items and paid income tax	41	38	-14	114
Change in working capital	35	76	-549	-324
Cash flow from operating activities	**427**	**656**	**1,407**	**1,874**
Cash flow from investing activities	-85	-193	-1,129	-500
Cash flow from financing activities	-33	-20	-862	-552
Cash flow for the period	**309**	**443**	**-585**	**822**
Cash and cash equivalents, opening balance	2,002	2,532	3,014	2,140
Exchange difference for cash and cash equivalents	11	39	-107	53
Cash and cash equivalents, closing balance	**2,323**	**3,014**	**2,323**	**3,014**

Consolidated statement of changes in equity in summary, SEK million	Jan-Dec 2025	Jan-Dec 2024
Opening balance	**6,575**	**5,282**
Dividend to owners	-734	-441
Change of non-controlling interests*	-32	-
Repurchase of own shares	-19	-19
Equity-settled share based payments	20	20
Total comprehensive income	1,300	1,731
Closing balance	**7,109**	**6,575**
Of which holdings of non-controlling interests	-	43

*Pertains to the acquisition of the non-controlling interest in Shenzhen Huan Cheng Xin Precision Manufacture Co., Ltd.

Other key figures*	Jan-Dec 2025	Jan-Dec 2024
Equity per share, SEK**	36.41	33.68
Return on equity (rolling 12 months), %	22.8%	28.5%
Return on capital employed (rolling 12 months), %	27.9%	34.1%
Net cash, SEK million	1,974	2,795
Average number of employees	2,427	2,158

*In addition to the performance indicators presented on page 1. See calculations on page 21.
**Recalculated to reflect the share split executed on June 3, 2025, whereby one existing share was split into two shares.

MYCRONIC

Parent Company

Profit/loss accounts in summary, Parent Company, SEK million	Q4 2025	Q4 2024	Jan-Dec 2025	Jan-Dec 2024
Net sales	901	1,025	4,218	4,062
Cost of goods sold	-473	-467	-1,732	-1,590
Gross profit	**428**	**558**	**2,486**	**2,472**
Other operating expenses	-318	-173	-1,369	-872
EBIT	**110**	**385**	**1,117**	**1,600**
Result from financial items	197	130	258	218
Profit/loss after financial items	**307**	**514**	**1,374**	**1,818**
Appropriations	-114	-296	-114	-296
Profit/loss before tax	**193**	**218**	**1,260**	**1,521**
Tax	-14	-38	-240	-306
Net Profit/loss	**179**	**179**	**1,020**	**1,215**

Statement of comprehensive income, Parent Company, SEK million	Q4 2025	Q4 2024	Jan-Dec 2025	Jan-Dec 2024
Net Profit/loss	179	179	1,020	1,215
Other comprehensive income	-	-	-	-
Total comprehensive income	**179**	**179**	**1,020**	**1,215**

Balance sheets in summary, Parent Company, SEK million	31 Dec 25	31 Dec 24
ASSETS		
Non-current assets		
Intangible and tangible assets	245	248
Financial assets	4,158	3,433
Total non-current assets	**4,402**	**3,681**
Current assets		
Inventories	977	917
Current receivables	944	942
Cash and cash equivalents	1,378	2,084
Total current assets	**3,299**	**3,943**
TOTAL ASSETS	**7,701**	**7,624**
EQUITY AND LIABILITIES		
Equity	**4,390**	**4,103**
Untaxed reserves	**1,784**	**1,670**
Provisions	**17**	**22**
Non-current liabilities		
Non-current interest-bearing liabilities	-	-
Other non-current liabilities	56	-
Total non-current liabilities	**56**	**-**
Current liabilities		
Current interest-bearing liabilities	-	-
Other current liabilities	1,454	1,829
Total current liabilities	**1,454**	**1,829**
TOTAL EQUITY AND LIABILITIES	**7,701**	**7,624**

Notes

NOTE 1 ACCOUNTING POLICIES

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting, along with applicable provisions in the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with Chapter 9 of the Swedish Annual Accounts Act. For the Group and Parent Company, accounting policies, valuation policies and assumptions were applied in accordance with the latest annual report. The accounting policies of the segments are the same as for the Group, with the exception of IFRS 16 Leases. The segments and the Parent Company recognize lease payments as a cost on a straight-line basis over the term of the lease. The right-of-use asset and the lease liability are thus not reported in the balance sheet.

The nature of financial assets and liabilities is, in all material respects, the same as on December 31, 2024. The carrying amounts and fair values are deemed to essentially correspond with one another.

In relation to the acquisition of the previously held non-controlling interest in Surfx Technologies made in 2020, the Group elected to classify irrevocably its equity investments in the company, as equity instruments designated at fair value through Other comprehensive income.

NOTE 2 RELATED PARTY TRANSACTIONS

A description of related party transactions can be found in Note 8 of the 2024 Annual Report. The scope and nature of these transactions did not change significantly during the period.

NOTE 3 RISKS AND UNCERTAINTIES

The Group's business is exposed to a number of risks and uncertainties that are both operational and financial in nature, most of which are presented in the 2024 Annual Report. Mycronic is a global company with customers and production sites in multiple geographies worldwide and is therefore exposed to political decisions, such as tariffs and trade barriers.

NOTE 4 EVENTS AFTER THE END OF THE PERIOD

After the end of the period, Global Technologies acquired ETZ, a company based in Germany, which manufactures test probes. ETZ's net sales in 2025 amounted to almost EUR 4 million, of which sales to Mycronic made up around 85 percent. The company will become part of the PCB Test business line within the Global Technologies division.

Orders were also received for a Prexision 8 Evo and an MMX.

NOTE 5 REVENUE FROM CONTRACTS WITH CUSTOMERS

	Q4		Jan-Dec	
Revenue by geographical market, SEK million	**2025**	**2024**	**2025**	**2024**
EMEA	261	303	918	931
North and South America	451	261	1,146	899
Asia	1,309	1,494	5,874	5,228
	2,021	**2,059**	**7,938**	**7,057**
Revenue by type of good/service, SEK million				
System	1,510	1,543	5,962	5,312
Aftermarket	511	516	1,977	1,745
	2,021	**2,059**	**7,938**	**7,057**
Timing of revenue recognition, SEK million				
Goods transferred at a point in time	1,694	1,748	6,674	5,890
Services transferred over time	326	311	1,264	1,168
	2,021	**2,059**	**7,938**	**7,057**

NOTE 6 OPERATING SEGMENT REPORTING

	Q4		Jan-Dec	
SEK million	**2025**	**2024**	**2025**	**2024**
Net sales by Division				
Pattern Generators	577	702	3,232	2,997
PCB Assembly Solutions	438	486	1,372	1,489
High Volume	448	467	1,720	1,434
Global Technologies	570	403	1,632	1,138
Internal net sales between divisions	-13	-	-18	-
	2,021	**2,059**	**7,938**	**7,057**
EBIT by Division				
Pattern Generators	173	311	1,623	1,694
PCB Assembly Solutions	59	106	79	156
High Volume	55	76	267	223
Global Technologies	118	86	225	113
Group functions etc	-66	-56	-259	-175
Effects from IFRS 16	2	4	6	8
Group	**342**	**527**	**1,940**	**2,021**

SEK million	31 Dec 25	31 Dec 24
Assets by Division		
Capitalized Development Costs		
Pattern Generators	96	91
PCB Assembly Solutions	73	82
High Volume	5	4
Global Technologies	11	-
	185	**177**
Inventories		
Pattern Generators	722	661
PCB Assembly Solutions	446	425
High Volume	629	684
Global Technologies	353	288
Unrealized profit in inventories	-1	-1
	2,150	**2,056**
Trade Receivables		
Pattern Generators	318	411
PCB Assembly Solutions	340	400
High Volume	305	448
Global Technologies	374	248
	1,336	**1,507**

NOTE 7 R&D COSTS

	Q4		Jan-Dec	
Research and development costs, SEK million	**2025**	**2024**	**2025**	**2024**
R&D expenditures				
Pattern Generators	-124	-106	-445	-332
PCB Assembly Solutions	-50	-51	-197	-207
High Volume	-54	-43	-183	-154
Global Technologies	-52	-31	-170	-101
	-280	**-231**	**-994**	**-793**
Capitalization of Development Costs				
Pattern Generators	7	16	25	45
PCB Assembly Solutions	7	8	26	36
High Volume	0	0	2	4
Global Technologies	2	-	11	-
	16	**25**	**64**	**84**
Amortization of Acquired Technology				
PCB Assembly Solutions	0	-1	-2	-5
High Volume	0	0	-2	0
Global Technologies	-12	-8	-45	-32
	-13	**-10**	**-48**	**-37**
Reported cost	**-277**	**-216**	**-978**	**-747**

NOTE 8 BUSINESS COMBINATIONS

Acquisition of Hprobe SA

In March, 2025, Mycronic acquired Hprobe SA, a company headquartered in Grenoble, France. The company is a leader in the emerging niche market of MRAM (Magnetoresistive Random Access Memory) testing and manufactures equipment for high-speed magnetic testing of MRAMs and magnetic sensors. Hprobe was founded in 2017, had 14 employees, and net sales amounted to EUR 4 million in 2024. Hprobe forms a new business line within the Global Technologies division, called Magnetic Test. The purchase consideration amounts to EUR 16 million, corresponding to SEK 177 million, on a cash and debt-free basis.

Work to assign values to acquired assets and liabilities is ongoing and the purchase price allocation is therefore still preliminary as of December 31, 2025. In the preliminary purchase price allocation, intangible assets in technology, customer relationships, brand and goodwill were identified. Goodwill amounts to SEK 116 million and is primarily attributable to the company's leading position as a supplier of equipment for high-speed magnetic testing of MRAMs and magnetic sensors, as well as the collective expertise of its employees. The company was consolidated in the Mycronic Group as of March 13, 2025. Hprobe's operations contributed SEK 75 million to consolidated net sales in 2025 whereas EBIT was negatively impacted by SEK 9 million.

Acquisition of RoBAT Limited

In April, 2025, RoBAT was acquired, a company headquartered in the United Kingdom, which has developed a technology for fast and reliable tests of signal quality on PCBs. The company was founded in 2001, with 27 employees, and offices in the United Kingdom, the US and China. Net sales in 2024 amounted to GBP 3 million. Following the transaction, RoBAT becomes part of the PCB Test business line within the Global Technologies division. The purchase consideration amounts to GBP 7.5 million, corresponding to SEK 97 million, on a cash and debt-free basis. Under certain conditions, based on parameters such as sales and earnings, an additional purchase consideration of a maximum of GBP 4 million could be disbursed in 2028.

Work to assign values to acquired assets and liabilities is ongoing and the purchase price allocation is therefore still preliminary as of December 31, 2025. In the preliminary purchase price allocation, intangible assets in technology, customer relationships, brand and goodwill were identified. Goodwill amounts to SEK 61 million and is primarily attributable to RoBAT's specialized technology for high-frequency signal quality testing of bare board PCBs, which complements and enhances Mycronic's existing offering within the PCB Test business line. The acquisition price is adjusted for contingent considerations, which are deemed to correspond to fair value. As of December 31, 2025, a contingent consideration has been recorded of GBP 2.7 million, an equivalent of SEK 34 million. The contingent consideration is recorded as Other non-current liabilities in the consolidated statements of financial position in summary. The company was consolidated in the Mycronic Group as of April 4, 2025. RoBAT's operations contributed SEK 52 million to consolidated net sales in 2025 whereas EBIT was negatively impacted by SEK 8 million.

Acquisition of Surfx Technologies LLC

In June, 2025, Surfx Technologies was acquired, a company headquartered in the US, providing atmospheric plasma solutions for surface treatment, including cleaning and active oxide removal. These solutions are used in advanced packaging, semiconductor processing, and other electronics manufacturing applications. Surfx forms a new business line within the Global Technologies division, called Applied Plasma. Surfx was founded in 1999, with 34 employees located in the US and Taiwan. Mycronic made a minor investment in Surfx in 2020 and previous to the acquisition owned 7.5 percent of the company. The total consideration amounts to USD 87.5 million, corresponding to SEK 840 million, on a cash and debt-free basis. This includes previously held non-controlling interests. Out of the total consideration, USD 5 million is paid as a retention incentive to the founder and the employees, which was expensed during 2025. Under certain conditions, based on sales criteria, an additional consideration of a maximum of USD 57.8 million could be disbursed in 2026-2028, whereof USD 9.4 million pertains to the retention incentive program and therefore expensed during the qualifying period in relation to the expected outcome.

Work to assign values to acquired assets and liabilities is ongoing and the purchase price allocation is therefore still preliminary as of December 31, 2025. In the preliminary purchase price allocation, intangible assets in technology, customer relationships, brand and goodwill were identified. Goodwill amounts to SEK 596 million and is primarily attributable to the company's leading position in atmospheric plasma solutions. Additionally, the collective expertise of Surfx's skilled employees in the field of plasma technology plays a key role in enabling Mycronic to enhance its product offerings in 3D die stacking, which is critical for the advancement of AI technologies. The acquisition price is adjusted for contingent considerations, which are deemed to correspond to fair value. As of December 31, 2025, a contingent consideration has been recorded of USD 10.5 million, an equivalent of SEK 97 million. The contingent consideration is recorded as Other non-current liabilities in the consolidated statements of financial position in summary. The company was consolidated in the Mycronic Group as of June 3, 2025. Surfx's operations contributed SEK 139 million to consolidated net sales in 2025 whereas EBIT was negatively impacted by SEK 39 million.

	Hprobe	RoBAT	Surfx
SEK million	**2025**	**2025**	**2025**
Acquisition price			
Cash paid for the acquisition	172	97	768
Fair value of previously held non-controlling interest	-	-	59
Contingent considerations (estimated fair value)	-	18	96
Total	**172**	**115**	**923**
Acquired assets and liabilities at fair value			
Intangible assets	68	31	315
Property, plant and equipment	3	10	4
Non-current receivables	6	0	0
Inventories	10	18	35
Current receivables	29	10	16
Cash and cash equivalents	27	6	83
Non-current liabilities	-32	-9	-58
Current liabilities	-56	-13	-68
Total	**56**	**53**	**327**
Goodwill	**116**	**61**	**596**
Changes in consolidated cash and cash equivalents as of the acquisition			
Cash paid for the acquisition	172	97	768
Cash and cash equivalents in acquired subsidiaries	-27	-6	-83
Total	**144**	**90**	**685**

NOTE 9 DEFINITIONS AND RECONCILIATION ALTERNATIVE PERFORMANCE MEASURES, ETC

The European Securities and Markets Authority (ESMA) has issued guidelines regarding alternative performance measures for listed companies.

These relate to financial key figures used by management, to control and evaluate the Group's business, which cannot be directly inferred from the financial statements. Alternative performance measures are also considered to be of interest to external investors and analysts who monitor the company. For definitions of other key ratios, please refer to the Annual Report.

Acquisition-related costs

Acquisition-related costs include expensing of acquired inventories at fair value, amortization and impairment of acquired intangible assets, changes in value and revaluation of contingent considerations and transaction costs etc.

Book-to-bill

Order intake in relation to net sales. Used to show future development of net sales.

Capital employed

Balance sheet total less non-interest bearing liabilities. Used to show the ability to meet capital needs from operations.

Earnings per share

Net profit/loss attributable to the owners of the Parent Company divided by the average number of outstanding shares before and after dilution. Used to show the company's earnings per share.

EBITDA

Operating result, EBIT, before depreciation and amortization.

Equity per share

Equity on balance day divided by the number of outstanding shares at the end of the period. Used to measure the value of the company per share.

Net cash

Cash and cash equivalents less interest-bearing liabilities.

Order backlog

Remaining orders for goods, valued at the closing date exchange rate. Used to show secured future net sales of goods.

Order intake

Orders received for goods and services, valued at average exchange rates. The order intake also includes revaluation of the order backlog at closing date exchange rates. Used to show orders received.

Organic growth

Change in net sales, excluding increase related to acquisitions and decrease related to divestments, recalculated to the previous year's exchange rates as a percentage of the previous year's net sales. Net sales from acquired companies are included in the calculation of organic growth as of the first day of the first month which falls 12 months after the date of acquisition.

Return on capital employed

Profit before financial expenses as a percentage of average capital employed. Used to show return on capital needed for operations.

Return on equity

Net profit/loss as a percentage of average equity. Used to show return on shareholder capital over time.

Underlying EBIT and underlying EBIT margin

Underlying EBIT consists of operating result excluding acquisition-related costs and gains/losses from divestments of subsidiaries. The underlying EBIT margin is underlying EBIT as a percentage of net sales. Used to describe how operations are developing and performing excluding acquisition-related costs and gains/losses from divestments.

	Jan-Dec	
Return on equity	**2025**	**2024**
Net profit/loss (rolling 12 months)	1,560	1,688
Average shareholders' equity	6,842	5,928
	22.8%	**28.5%**
Return on capital employed		
Profit/loss before tax (rolling 12 months)	1,970	2,084
Financial expenses	17	15
Profit/loss before financial expenses	**1,987**	**2,099**
Average balance sheet total	10,667	9,376
Average non-interest-bearing liabilities	3,541	3,224
Average capital employed	**7,126**	**6,152**
	27.9%	**34.1%**
Book-to-bill		
Order intake	7,757	7,611
Net sales	7,938	7,057
	1.0	**1.1**
EBITDA		
EBIT	1,940	2,021
Depreciation/Amortization	330	266
	2,270	**2,287**
Underlying EBIT		
EBIT	1,940	2,021
Acquisition-related costs included in:		
Cost of goods sold	39	2
Operating expenses	157	72
	196	74
	2,136	**2,095**
Equity per share*		
Equity at balance day	7,109	6,575
No. of outstanding shares at end of period, thousand*	195,270	195,180
	36.41	**33.68**
Earnings per share before/after dilution, SEK*		
Net Profit/loss attributable to owners of the Parent Company	1,560	1,683
Average no. of outstanding shares before dilution, thousand*	195,201	195,180
	7.99	**8.62**
Average no. of outstanding shares after dilution, thousand*	195,281	195,289
	7.99	**8.62**
Net cash, SEK million		
Cash and cash equivalents	2,323	3,014
Interest-bearing liabilities	-348	-219
	1,974	**2,795**

*Recalculated to reflect the share split executed on June 3, 2025, whereby one existing share was split into two shares.

MYCRONIC

Quarterly data	Q4 25	Q3 25	Q2 25	Q1 25	Q4 24	Q3 24	Q2 24	Q1 24
Order intake								
Pattern Generators	545	789	191	956	1,144	274	1,199	645
PCB Assembly Solutions	362	405	356	295	389	385	362	334
High Volume	271	444	383	553	387	389	357	390
Global Technologies	773	797	402	254	461	411	207	277
Internal order intake between divisions	-13	-4	-2	-	-	-	-	-
	1,939	**2,431**	**1,330**	**2,058**	**2,381**	**1,459**	**2,125**	**1,645**
Order Backlog								
Pattern Generators	2,582	2,614	2,309	3,092	3,334	2,891	3,424	2,876
PCB Assembly Solutions	147	224	133	105	102	199	167	158
High Volume	683	860	915	975	752	832	778	741
Global Technologies	1,269	1,066	711	445	514	457	330	327
	4,681	**4,763**	**4,068**	**4,617**	**4,702**	**4,379**	**4,700**	**4,102**
Net Sales								
Pattern Generators	577	485	974	1,197	702	807	650	838
PCB Assembly Solutions	438	314	328	292	486	353	353	296
High Volume	448	499	443	330	467	336	320	311
Global Technologies	570	416	323	323	403	284	203	247
Internal net sales between divisions	-13	-4	-2	-	-	-	-	-
	2,021	**1,709**	**2,066**	**2,142**	**2,059**	**1,780**	**1,527**	**1,692**
Gross Profit								
Pattern Generators	335	286	675	912	444	589	438	635
PCB Assembly Solutions	177	113	122	107	219	136	140	107
High Volume	184	192	170	143	163	134	131	128
Global Technologies	256	216	136	148	179	98	74	104
	945	**805**	**1,103**	**1,310**	**1,004**	**958**	**783**	**974**
Gross Margin								
Pattern Generators	58.2%	59.0%	69.4%	76.2%	63.3%	72.9%	67.3%	75.8%
PCB Assembly Solutions	40.5%	36.0%	37.2%	36.8%	45.0%	38.6%	39.7%	36.1%
High Volume	41.1%	38.5%	38.5%	43.5%	34.8%	39.9%	40.9%	41.1%
Global Technologies	44.9%	51.8%	42.2%	45.8%	44.4%	34.5%	36.3%	42.1%
	46.8%	**47.1%**	**53.4%**	**61.1%**	**48.8%**	**53.8%**	**51.3%**	**57.6%**
R&D expenses								
Pattern Generators	-117	-95	-108	-100	-91	-68	-65	-63
PCB Assembly Solutions	-44	-37	-45	-47	-43	-38	-48	-46
High Volume	-54	-46	-43	-40	-44	-39	-35	-33
Global Technologies	-63	-59	-47	-35	-39	-33	-34	-27
Total R&D expenses	**-277**	**-237**	**-242**	**-222**	**-216**	**-179**	**-182**	**-170**
Selling expenses	-210	-191	-172	-175	-172	-148	-173	-135
Administrative expenses	-121	-115	-114	-106	-102	-80	-94	-85
Other income/expenses	5	-7	-6	-31	12	-4	15	15
EBIT	**342**	**255**	**568**	**775**	**527**	**547**	**348**	**599**
Of which EBIT Pattern Generators	173	161	537	752	311	498	342	543
Of which EBIT PCB Assembly Solutions	59	20	14	-13	106	31	18	1
Of which EBIT High Volume	55	79	74	59	76	47	45	55
Of which EBIT Global Technologies	118	42	11	54	86	13	-15	30
Of which EBIT Group functions etc	-66	-48	-69	-77	-56	-44	-43	-31
EBIT margin	16.9%	14.9%	27.5%	36.2%	25.6%	30.7%	22.8%	35.4%
Equity per share*	36.41	35.55	34.73	36.18	33.68	31.11	28.91	29.89
Earnings per share before dilution*	1.42	1.11	2.28	3.18	2.36	2.30	1.47	2.50
Earnings per share after dilution*	1.42	1.11	2.28	3.18	2.35	2.30	1.47	2.50
Closing share price*	223.25	214.95	201.80	210.00	199.70	197.50	204.30	189.00

*Recalculated to reflect the share split executed on June 3, 2025, whereby one existing share was split into two shares.